FDA Approves Accord BioPharma’s Denosumab Biosimilars

Start
On November 20, 2025, the FDA approved Accord BioPharma’s denosumab biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu), which reference Amgen’s PROLIA® and XGEVA®, respectively. This marks the eighth set of denosumab biosimilars approved by the FDA….
By: Goodwin
Previous Story

Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved

Next Story

Federal Circuit Patent Watch: Petitioner Has No Right to Appeal “Deinstitution” of IPRs